Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?

References

• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders DSM-IV-TR Fourth Edition4th edWashington, DCAmerican Psychiatric Publishing, Inc2000
   Google Scholar
• LehmanAFLiebermanJADixonLBPractice guideline for the treatment of patients with schizophrenia, second editionAm J Psychiatry2004161Suppl 215615000267
   PubMed Web of Science ®Google Scholar
• PhillipsMRZhangJShiQPrevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001–2005: an epidemiological surveyLancet200937396802041205319524780
   PubMed Web of Science ®Google Scholar
• PhillipsMRCharacteristics, experience, and treatment of schizophrenia in ChinaDialogues Clin Neurosci20013210911922033637
   PubMedGoogle Scholar
• BuckleyPFWirshingDABhushanPPierreJMResnickSAWirshingWCLack of insight in schizophrenia: impact on treatment adherenceCNS Drugs200721212914117284095
   PubMed Web of Science ®Google Scholar
• Le QuachPMorsOChristensenTPredictors of poor adherence to medication among patients with first-episode schizophrenia-spectrum disorderEarly Interv Psychiatry20093667421352177
   PubMed Web of Science ®Google Scholar
• NovickDHaroJMSuarezDPerezVDittmannRWHaddadPMPredictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophreniaPsychiatry Res20101762–310911320185182
   PubMed Web of Science ®Google Scholar
• MathersCBoermaTFatDMThe Global Burden of Disease: 2004 UpdateGeneva, SwitzerlandWorld Health Organization2008
   Google Scholar
• PhillipsMRLuSHWangRWEconomic reforms and the acute inpatient care of patients with schizophrenia: the Chinese experienceAm J Psychiatry19971549122812349286181
   PubMed Web of Science ®Google Scholar
• XiangYTWangCYWangYSocio-demographic and clinical determinants of quality of life in Chinese patients with schizophrenia: a prospective studyQual Life Res201019331732220135234
   PubMed Web of Science ®Google Scholar
• XiangYTWangCYWengYZPredictors of relapse in Chinese schizophrenia patients: a prospective, multi-center studySoc Psychiatry Psychiatr Epidemiol201146121325133021046070
   PubMed Web of Science ®Google Scholar
• XiangYTWengYZLeungCMTangWKUngvariGSQuality of life of Chinese schizophrenia outpatients in Hong Kong: relationship to sociodemographic factors and symptomatologyAust N Z J Psychiatry200741544244917464737
   PubMed Web of Science ®Google Scholar
• YeungFChanSClinical characteristics and objective living conditions in relation to quality of life among community-based individuals of schizophrenia in Hong KongQual Life Res20061591459146916957873
   PubMed Web of Science ®Google Scholar
• FalkaiPWobrockTLiebermanJGlenthojBGattazWFMöllerH-JWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophreniaWorld J Biol Psychiatry20056313219116173147
   PubMed Web of Science ®Google Scholar
• LeuchtSKisslingWDavisJMSecond-generation antipsychotics for schizophrenia: can we resolve the conflict?Psychol Med200939101591160219335931
   PubMed Web of Science ®Google Scholar
• LeuchtSCorvesCArbterDEngelRRLiCDavisJMSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysisLancet20093739657314119058842
   PubMed Web of Science ®Google Scholar
• AnFRXiangYTWangCYChange of psychotropic drug prescription for schizophrenia in a psychiatric institution in Beijing, China between 1999 and 2008Int J Clin Pharmacol Ther201048427027420353748
   PubMed Web of Science ®Google Scholar
• PrahPPetersenINazarethIWaltersKOsbornDNational changes in oral antipsychotic treatment for people with schizophrenia in primary care between 1998 and 2007 in the United KingdomPharmacoepidemiol Drug Saf201221216116921858898
   PubMed Web of Science ®Google Scholar
• AttardATaylorDMComparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?CNS drugs201226649150822668246
   PubMed Web of Science ®Google Scholar
• LeuchtSKomossaKRummel-KlugeCA meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophreniaAm J Psychiatry2009166215216319015230
   PubMed Web of Science ®Google Scholar
• AllisonDBMentoreJLHeoMAntipsychotic-induced weight gain: a comprehensive research synthesisAm J Psychiatry1999156111686169610553730
   PubMed Web of Science ®Google Scholar
• Rummel-KlugeCKomossaKSchwarzSHead-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysisSchizophr Res20101232–322523320692814
   PubMed Web of Science ®Google Scholar
• FaulknerGCohnTRemingtonGInterventions to reduce weight gain in schizophreniaSchizophr Bull200733365465617449900
   PubMed Web of Science ®Google Scholar
• HoffmannVPCaseMJacobsonJGAssessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label studyJ Clin Psychiatry201273221622321672497
   PubMed Web of Science ®Google Scholar
• BonfioliEBertiLGossCMuraroFBurtiLHealth promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trialsBMC Psychiatry20121217822789023
   PubMed Web of Science ®Google Scholar
• GabrieleJMDubbertPMReevesRREfficacy of behavioural interventions in managing atypical antipsychotic weight gainObes Rev200910444245519389059
   PubMed Web of Science ®Google Scholar
• CentorrinoFWurtmanJJDucaKAWeight loss in overweight patients maintained on atypical antipsychotic agentsInt J Obes (Lond)20063061011101616432547
   PubMed Web of Science ®Google Scholar
• PoulinMJChaputJPSimardVManagement of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programmeAust N Z J Psychiatry2007411298098917999270
   PubMed Web of Science ®Google Scholar
• BallMPCoonsVBBuchananRWA program for treating olanzapine-related weight gainPsychiatr Serv200152796796911433117
   PubMed Web of Science ®Google Scholar
• ChenCKChenYCHuangYSEffects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow upPsychiatry Clin Neurosci2009631172219067997
   PubMed Web of Science ®Google Scholar
• AngQTangJZhaoJFactors associated with weight gain during six-month olanzapine therapyChin J Psychiatry2011443
   Google Scholar
• TreuerTHoffmannVPChenAK-PFactors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational studyWorld J Biol Psychiatry2009104 Pt 372974019606406
   PubMed Web of Science ®Google Scholar
• HaroJMEdgellETNovickDEffectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) studyActa Psychiatr Scand2005111322023115701107
   PubMed Web of Science ®Google Scholar
• LeuchtSTardyMKomossaKHeresSKisslingWDavisJMMaintenance treatment with antipsychotic drugs for schizophreniaCochrane Database Syst Rev20125CD00801622592725
   PubMed Web of Science ®Google Scholar
• GuoXZhaiJLiuZEffect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: a randomized, 1-year studyArch Gen Psychiatry201067989590420819983
   PubMed Web of Science ®Google Scholar
• GaebelWRiesbeckMvon WilmsdorffMDrug attitude as predictor for effectiveness in first-episode schizophrenia: results of an open randomized trial (EUFEST)Eur Neuropsychopharmacol201020531031620202800
   PubMed Web of Science ®Google Scholar
• HaroJMSuarezDNovickDBrownJUsallJNaberDThree-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies resultsEur Neuropsychopharmacol200717423524417137759
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHStenslandMDKinonBJTollefsonGDWeight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychoticJ Psychopharmacol200519Suppl 611011716280344
   PubMedGoogle Scholar
• TreuerTKaragianisJHoffmannVPCan increased food intake improve psychosis? A brief review and hypothesisCurr Mol Pharmacol20081327027220021439
   PubMedGoogle Scholar
• TreuerTKaragianisJIs hunger a driver of the cognitive development?Neuropsychopharmacology2006311023262327 author reply 232816980985
   PubMed Web of Science ®Google Scholar
• BusheCJSlooffCJHaddadPMKaragianisJLWeight change from 3-year observational data: findings from the worldwide schizophrenia outpatient health outcomes databaseJ Clin Psychiatry2012736e749e75522795214
   PubMedGoogle Scholar
• MillenBACampbellGMBeasleyCMWeight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trialsJ Psychopharmacol201125563964520558497
   PubMed Web of Science ®Google Scholar
• TreuerTPendleburyJLockmanHWeight Gain Risk Factor assessment checklist: overview and recommendation for useNeuro Endocrinol Lett201132219920521552187
   PubMed Web of Science ®Google Scholar
• BassonBRKinonBJTaylorCCSzymanskiKAGilmoreJATollefsonGDFactors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidoneJ Clin Psychiatry200162423123811379836
   PubMed Web of Science ®Google Scholar
• ChoongEBondolfiGEtterMPsychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric populationJ Psychiatr Res201246454054822316639
   PubMed Web of Science ®Google Scholar
• LeeSYParkMHPatkarAAPaeCUA retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidoneProg Neuropsychopharmacol Biol Psychiatry201135249049621146575
   PubMed Web of Science ®Google Scholar
• CaseMTreuerTKaragianisJHoffmannVPThe potential role of appetite in predicting weight changes during treatment with olanzapineBMC Psychiatry2010107220840778
   PubMed Web of Science ®Google Scholar
• GrantPMHuhGAPerivoliotisDStolarNMBeckATRandomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophreniaArch Gen Psychiatry201269212112721969420
   PubMed Web of Science ®Google Scholar